Good Start Genetics Launches EmbryVu™, Affordable PGS Testing

Sigue a El Diario NY en Facebook

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Good Start Genetics, Inc., a commercial-stage molecular genetics
information company, announced today the availability of EmbryVu,
a new preimplantation genetic screening (PGS) test. PGS improves the
chances of successful in vitro fertilization (IVF) by identifying
embryos that have an increased chance of implantation and successful
pregnancy. Good Start Genetics is offering EmbryVu at
considerably lower prices than other PGS tests currently on the market.

The process begins with the safe removal of a few cells from embryos
created during the IVF process. EmbryVu tests for the presence or
absence of whole chromosomes in each sample to determine those with the
expected number. Embryos found to have more or fewer chromosomes than
expected are referred to as aneuploid, and can fail to implant or result
in miscarriage. Because EmbryVu will help fertility specialists
select embryos for transfer that have a normal chromosome complement, it
is expected to significantly increase the chances of a successful
pregnancy. Good Start Genetics is offering this service at considerably
lower prices than other PGS products currently available, enabling IVF
clinicians to offer PGS more widely.

In December of 2014, Good Start Genetics entered into an exclusive
license agreement with Johns Hopkins University (JHU) for FAST-SeqS, the
Fast Aneuploidy Screening Test-Sequencing System, invented by Drs. Bert
Vogelstein, Ken Kinzler, Isaac Kinde, and Nickolas Papadopoulos of JHU,
which enables the screening of embryos for chromosome abnormalities
prior to implantation in an IVF setting.

“Advances in infertility medicine are being made every day that are
helping people realize their dream of building a family,” said Barbara
Collura, president and chief executive officer of RESOLVE: The National
Infertility Association, a non-profit organization improving the lives
of people living with infertility. “For more than 40 years, RESOLVE’s
mission has been to support those who are having trouble conceiving
while raising awareness and advocating for the infertility community. We
applaud healthcare providers, scientists and researchers that are
advancing the field and science and offering treatments, products, and
services that help people build their families.”

“Good Start Genetics is an ally for those striving to conceive, and we
expect that our research in PGS and the development of EmbryVu
will help IVF couples get one step closer,” said Don Hardison, president
and chief executive officer of Good Start Genetics. “Partnerships with
highly respected groups like RESOLVE allow us to communicate and work
with families navigating through the IVF process in achieving their goal
of a healthy pregnancy.”

EmbryVu is available through IVF centers across the country.

About Good Start Genetics®, Inc.

Good Start Genetics is a molecular genetics information company
transforming the standard of care in reproductive medicine. Its suite of
reproductive genetics products provides clinicians and patients with
insightful and actionable information in order to promote successful
pregnancies and healthy families. Its flagship genetic carrier screening
service, GeneVu™, is a comprehensive menu of highly-accurate
tests for known and novel mutations that cause inherited genetic
disorders, and its advanced preimplantation genetic screening test, EmbryVu™,
is helping a wider range of couples find their paths to pregnancy at
significantly lower costs. Good Start Genetics complements these tests
and its proprietary next-generation DNA sequencing (NGS) capabilities
with world-class customer care and thoughtful genetic counseling to help
families prepare for tomorrow. For more information, please visit www.goodstartgenetics.com.

About RESOLVE: The National Infertility Association: Established
in 1974, RESOLVE: The National Infertility Association is a non-profit
organization with the only established, nationwide network mandated to
promote reproductive health and to ensure equal access to all family
building options for men and women experiencing infertility or other
reproductive disorders. One in eight U.S. couples of childbearing age is
diagnosed with infertility. RESOLVE addresses this public health issue
by providing community to these women and men, connecting them with
others who can help, empowering them to find resolution and giving voice
to their demands for access to all family building options. For more
information, visit www.RESOLVE.org

Contacts

Media Contacts
Good Start Genetics
Bob Rochelle,
617-714-0825
brochelle@gsgenetics.com
or
Racepoint
Global
Ashley Benisatto, 617-624-3200
goodstartgenetics@racepointglobal.com